Over the past ten years, our company's operations have centered on accurately simulating the development and dynamic organization of living tissue and its
constituent cells. These efforts impact scientific research in areas such as
biology, medicine, agriculture and energy.
Our activities have focused on bio-medical research and the development of enabling technologies to provide life scientists with new, broadly applicable tools: to investigate stem cell mechanisms, to speed the development of new drug therapies, or to better understand tissue regeneration, for example. In addition, the emerging fields of synthetic biology, bio-engineering, and bio- fuel alternatives provide promising opportunities in the near future.
Equally exciting is the portfolio of intellectual property we have derived over the course of
the last decade in developing our core business.
We are an Idaho company with 10 employees and a Board of Directors comprising seven members. There
are nineteen shareholders who own 1.4M shares. Combined funding to
date has totaled more than $9M.
With over 20 patents to date, both issued and pending, we are making significant technical
contributions in fields such as collision detection used in computer
graphics, complex data profiling, synthetic biology, and cancer
We are beginning the process of key technology transfers which stand to substantially contribute
to our cash reserves as well as fund the significant growth we have
Through our wholly owned subsidiary, Endogenics, Inc., we are aggressively pursuing strategic
partnerships and collaborations to augment existing work and expand
into new research in cancer mechanisms, toxicology, stem cell biology
and protein therapeutics.